After completing installation, permitting and the testing phase, Chemesis has begun accepting orders of QuickStripTM Oral Thin Strips
VANCOUVER, British Columbia, Sept. 04, 2019 (GLOBE NEWSWIRE) — Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), is proud to announce its subsidiary, Natural Ventures, has completed the installation, permitting, and testing phase of its QuickStrip™ oral thin strip production equipment. The Company has completed the previously announcedcommercialization strategy, and has begun accepting orders for QuickStrip for immediate distribution across Puerto Rico and the United States.
Since receiving Gold Vendor Status from Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) Chemesis has continued to work diligently to ensure the QuickStrip go to market strategy is done effectively and efficiently. The Company expects to see a consistent increase in revenue as consumers move to a more Quick, Convenient, Precise, and Discrete™ method of consumption.
“Our partnership with RDT brings an incredible amount of potential growth for Chemesis,” said Chief Executive Officer of Chemesis, Edgar Montero. “The partnership gives Chemesis access to a large market of consumers that are looking for alternatives that provide a No Smoke, No Smell, No Stigma™ administration of THC or CBD.”
On behalf of the board of directors
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently operating within California, Puerto Rico, and finalizing an acquisition in Colombia.
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods to provide consumers with quality cannabis products.
Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering quality product to its consumers from seed to sale.
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn-key Managed Strip Service Program which enables RDT’s QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT’s service-based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. Rapid Dose Therapeutics is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs — including humans, animals and plants.
For more information, visit: www.rapid-dose.com
|For inquiries please contact:|
|Ian Fodie, CFO||Ali Mahdavi, Managing Director|
|Rapid Dose Therapeutics Corp.||Spinnaker Capital Markets Inc.|
|[email protected]||[email protected]|
|Office (416) 477-1052||Office (416) 962-3300|
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release